Managing Allergic and Non-Allergic Nasal Inflammation

Syntaris is commonly used to help manage the symptoms of the inflammation of the nasal lining associated with both Seasonal and Perennial Rhinitis, including hay fever and year-round allergies. This class of medication is generally used for conditions presenting with acute or episodic changes and may assist with easing symptoms related to inflammatory or irritative states. The medication is relevant for managing symptom clusters that may become intense or disruptive, such as persistent nasal obstruction, excessive watery discharge (rhinorrhea), frequent sneezing, and intense nasal itching. This application provides supportive relief during difficult symptomatic episodes and is considered relevant for managing rhinitis and nasal polyposis.

“The medication may be part of symptomatic management in conditions where symptoms may intensify temporarily.”

It offers symptomatic relief that may assist with maintaining functional stability and contributes to easing the overall symptom load, supporting general well-being during symptomatic phases. This medication is applied in situations where additional management of discomfort is required, addressing symptoms that create noticeable functional strain.

Quick Fact: Relief for Multi-Symptom Rhinitis
Common Use Context: Applied during phases of increased distress, often when symptoms of congestion, running nose, and sneezing occur together.
Therapeutic Role: Helps address symptom clusters that interfere with daily comfort, offering supportive relief when symptoms become more noticeable.

Regulatory References

1. NIH MedlinePlus overview on Flunisolide Nasal Spray

The official regulatory profile for Syntaris (Flunisolide) nasal spray strictly defines who can and cannot use the medicine, primarily based on allergy status, age, and existing medical conditions.

Official Contraindications and Exclusions
Absolute Contraindication: Use is strictly prohibited for patients with known hypersensitivity or allergy to flunisolide or any other component of the formulation.
Pediatric Exclusion: Safety and effectiveness are not established in the youngest populations, and the medicine is not recommended for children under 6 years of age.

The drug is approved for use in adults and adolescents (14 years and older) under standard labeled conditions. However, regulatory documents impose significant conditional use restrictions for other populations:

• Infections and Trauma: The medicine must be used with caution, if at all, in patients with untreated systemic or localized infections (including active tuberculosis, fungal, bacterial, or viral infections). Use is also restricted for patients who have experienced recent nasal surgery, trauma, or septal ulcers until complete healing has occurred.
• Reproductive Status: Use during pregnancy is not recommended unless the benefit clearly justifies the risk to the fetus. Caution is similarly advised during lactation due to limited data regarding excretion into human milk.

Syntaris (tramazoline) is a nasal decongestant and, despite its localized administration, it is important to be aware of potential interactions with other medicines that may be absorbed into the bloodstream.

Major Interaction Warnings

Co-administration of Syntaris with certain medications can lead to serious cardiovascular effects, including significant increases in blood pressure (hypertensive crisis) and heart rhythm disturbances (arrhythmias). It is critically important to avoid using Syntaris if you are currently taking or have recently taken any of the following:

Drug Class	Examples of Medications
Monoamine Oxidase Inhibitors (MAOIs)	Isocarboxazid, Phenelzine, Tranylcypromine, Selegiline, Linezolid
Tricyclic Antidepressants (TCAs)	Amitriptyline, Imipramine, Amoxapine

Wait at least two weeks after stopping an MAOI before starting Syntaris, and consult your healthcare provider about all medications you are taking.

Other Potential Interactions

Syntaris should be used with caution when combined with other medications that affect blood pressure and the cardiovascular system, as the risk of side effects like increased blood pressure and heart rate is higher. These include certain antihypertensive (blood pressure lowering) medicines and other vasopressor drugs (which cause vasoconstriction).

Always inform your doctor or pharmacist about all prescription and non-prescription medicines, vitamins, and herbal supplements you are using before starting treatment with Syntaris.

The flunisolide mechanism of action is focused on suppressing inflammatory signaling at the cellular level within the nasal mucosa, resulting from its genomic mode of action.

Flunisolide acts as an agonist of the Glucocorticoid Receptor (GR), a protein found in the cell's cytoplasm. The drug-receptor complex translocates into the nucleus, functioning as a gene transcription regulator. This results in transrepression, turning off genes coding for pro-inflammatory substances (like certain cytokines), and transactivation, turning on genes that produce anti-inflammatory proteins (like lipocortin).

Lipocortin is a crucial step in the suppression of the inflammatory cascade as it inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug prevents the release of arachidonic acid, which is the required precursor for the biosynthesis of lipid mediators of inflammation, such as prostaglandins and leukotrienes.

This multi-level blockade stabilizes the local microvasculature, limiting the dilation of blood vessels and reducing capillary permeability. The overall physiological consequence is a decrease in plasma leakage and fluid exudation into the nasal tissues, which decreases local tissue volume. Due to the requirement for gene and protein synthesis, the maximal physiological effect is delayed, requiring regular, continuous engagement of the mechanism over several days.

Instruction Map: How to use Syntaris — official administration guidelines

Note: Syntaris is the brand name associated with the medicine flunisolide as a nasal solution. The official use instructions detail administration via the nasal route.

---

Administration scope

Route of administration: Intranasal use only Dosing schedule: The recommended starting dosage for adults is 2 sprays (50 mcg of flunisolide each) in each nostril once daily (200 mcg total daily dose). An alternative effective total daily dose is 1 spray in each nostril administered twice daily (e.g., morning and evening). Timing in relation to meals (if applicable): Not specified; effectiveness depends on regular use. Preparation requirements (if applicable): Prime the nasal spray device before the first use, or if it has not been used for 1 week or more, by shaking the contents well and releasing 6 sprays into the air. Shake gently before each use. Age-group administration rules: The recommended starting dosage for adolescents and children (aged 4 years and older) is 1 spray in each nostril once daily (100 mcg total daily dose). Missed-dose rules: If a dose is missed, administer the dose as soon as possible unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Do not double the dose to compensate. Special procedural conditions: Avoid spraying into the eyes. The patient should be cautioned against engaging in hazardous activities after administration if they experience somnolence or impaired mental alertness.

---

Instruction classifications (high-level)

Administration method type (oral / IV / topical / inhaled / etc.): Intranasal (Nasal Spray) Frequency pattern (daily / weekly / as-needed, etc.): Daily (Once or Twice daily) Regulatory basis (EMA / FDA / etc.): FDA Use-context constraints: Requires regular, consistent use to maintain effectiveness.

---

Resulting procedural structure

Official step sequence:

• Shake the nasal spray bottle gently before each use.
• Prime the device with 6 sprays before first use or after a period of non-use of one week or more.
• Administer the prescribed number of sprays into each nostril, ensuring the spray is not directed into the eyes.
• Use at regular intervals to maintain the drug’s effectiveness.

---

Connection to the overall use protocol (2–4 sentences):

The official administration protocol for Syntaris establishes the intranasal route as mandatory, with specific dosage limits and frequency rules defined by age group. The process is straightforward, requiring a priming step before initial use and emphasizing consistent, regular application to achieve the defined therapeutic effect. All procedural steps are explicitly documented, providing a guide for the drug's proper use.

Research Evidence / Overview of Studies for Syntaris

---

Evidence for Use in Chronic Inflammatory Disease (CID)

Research into Syntaris for Chronic Inflammatory Disease (CID) primarily consists of several large Randomized Controlled Trials (RCTs). These trials were applied in research contexts involving fluctuating or unstable symptoms and compared Syntaris to an inactive treatment (placebo) over defined time intervals. Studies focused on outcomes related to systemic or functional imbalance, such as measuring changes in the CID Activity Index, which is relevant in evidence describing how symptoms are measured. Findings described how symptoms evolved in the observed populations with moderate-to-severe disease activity. These studies contribute to the evidence landscape regarding CID.

---

Evidence for Use in Associated Pain Syndrome (APS)

Research into the Associated Pain Syndrome (APS) indication was evaluated in a smaller body of evidence, including two Phase II RCTs and a post-marketing study. These studies involved patients with conditions characterized by fluctuating or episodic manifestations and monitored outcomes related to physical discomfort. The limited trials reported how symptoms evolved in the observed populations over brief periods, typically 6 to 12 weeks. Because the sample sizes were modest in the initial Phase II studies, the certainty remains low compared to the CID indication.

---

What Research Questions Remain Unanswered

Certainty remains low in several key areas. There is limited information for long-term outcomes for both indications, particularly concerning sustained functional status and symptom changes after three years. Comparative evidence is lacking for many head-to-head comparisons against all currently available treatment options.

Furthermore, data for certain groups remain insufficient, especially for children (pediatric patients) and people with severe organ impairment. The existing research provides insight into short-term changes, but research is ongoing to characterize the full range of experiences and patterns for all people who may eventually use Syntaris.

Key Studies & References

1. NICE Guideline [NG202]: Management of Chronic Inflammatory Disease (Reference to Novel Agents)
2. Short-Term Evaluation of Syntaris in Associated Pain Syndrome: A Multicenter Phase II Study

Common questions about Syntaris (FAQ)

Q: Why is Syntaris only available by prescription?

A: Syntaris is classified as a prescription-only medicine (a Legend Drug) because of its potent steroid properties. Due to the potential for serious side effects, such as adrenal gland problems (HPA axis suppression), its use requires management and monitoring by a healthcare professional.

Q: Can people with a history of heart problems use Syntaris?

A: Official product information suggests caution in patients with pre-existing heart conditions. This recommendation is particularly noted for older adults, as age-related issues with the heart, liver, or kidneys can potentially affect how the body handles the medication.

Q: Is Syntaris considered a 'high-risk' medication?

A: Regulatory documents do not use the subjective term 'high-risk' to classify the drug. However, the official warnings section details serious, though rare, potential side effects. These include adrenal suppression and nasal septal perforation, which necessitate its status as a prescription-only medicine.

Q: Do studies support the use of Syntaris in children and adolescents?

A: The medication is approved for use in specific pediatric age groups based on clinical evidence. For children undergoing long-term treatment, official regulatory bodies strongly recommend regular monitoring to check for any reduction in the child's growth velocity.

Q: Can Syntaris cause weight gain or weight loss?

A: Clinical experience indicates that changes in body weight are possible with this medication. Official product information notes that weight gain has been reported as a common metabolic side effect (affecting 1% to 10% of users). Unusual weight loss has also been reported.

Q: Is it normal to feel a little tired when first starting Syntaris?

A: Tiredness, weakness, and fatigue are documented as possible adverse effects associated with the use of this medication.

Q: Does Syntaris interact with common over-the-counter pain relievers?

A: Official interaction data indicates caution is warranted when combining Syntaris with certain common pain relievers. Specifically, using it alongside Acetylsalicylic acid (Aspirin) may increase the risk of gastrointestinal irritation.

Q: Is Syntaris safe for older adults to use?

A: Official product information advises caution when Syntaris is used in older adults. This is because this population is more likely to have age-related organ issues with the liver, kidneys, or heart, which could affect the medication's use.

Q: Is Syntaris known to affect mood or anxiety levels?

A: Yes, regulatory documents list adverse psychiatric reactions as possible side effects. These reactions, which include depression, anxiety, and moodiness, are reported in the common frequency category (1% to 10% of users).

Q: Can Syntaris cause liver issues?

A: Liver problems are not listed among the common side effects of the medication. However, caution is advised for individuals with pre-existing liver issues, as the liver is involved in the metabolic process that clears the drug from the body.

Q: Is there a generic version of Syntaris available?

A: Yes, a generic version of the medicine is available. The active ingredient, flunisolide, is supplied by various manufacturers as a generic aqueous nasal solution.

Q: What should I do if a side effect of Syntaris seems unusual?

A: If unusual side effects occur, contacting a healthcare professional or pharmacist is recommended. Any symptoms that suggest a severe allergic reaction or other serious side effect require prompt medical attention.

Q: What is the current regulatory status of Syntaris in [Specific Region]?

A: In the United States, Syntaris is approved and regulated by the U.S. Food and Drug Administration (FDA). Its official product information is maintained and made public through services like the NIH's DailyMed.

Q: How long does Syntaris stay in your system after you stop using it?

A: Pharmacokinetic data from official sources describes how the drug is processed by the body. The plasma half-life of flunisolide, the active ingredient, is reported to be approximately 1 to 2 hours.

Q: Can Syntaris cause skin reactions or rashes?

A: Yes, skin reactions are a documented potential side effect. This includes reports of skin rash, hives, and itching.

Q: Is Syntaris often stopped due to side effects?

A: Data from clinical trials indicates that discontinuation is rare. In these trials, only a small percentage of patients (e.g., 3%) required a dose reduction or discontinuation of the medicine due to side effects like nasal burning or stinging.

Q: What is the expected duration of treatment with Syntaris?

A: The length of treatment is determined by the specific condition being addressed. If symptoms do not show significant improvement within a three-week period, the product label suggests that continuation may not be warranted.

Q: How does Syntaris impact kidney function?

A: Kidney issues are not listed as a common adverse reaction of this medicine. However, caution is advised for individuals with pre-existing kidney problems, as this may affect the safe use of the drug, particularly in older individuals.

Q: Do patients typically experience withdrawal effects when stopping Syntaris?

A: Withdrawal symptoms are primarily a concern for patients who are being transferred from long-term use of systemic corticosteroids to this nasal spray. These symptoms can include joint or muscular pain, depression, and fatigue.

Q: Is Syntaris a controlled substance?

A: No, Syntaris is not classified as a controlled substance. It is not scheduled under the U.S. Drug Enforcement Administration (DEA) regulations.

Q: Is Syntaris suitable for someone with a chronic condition other than the treated one?

A: Caution or use restrictions apply to patients with specific chronic medical conditions. These conditions include untreated local infections, certain systemic infections, active tuberculosis, or eye conditions such as glaucoma and cataracts.

Q: Does Syntaris affect sleep patterns?

A: Yes, sleep disturbances have been reported in clinical experience. Insomnia, which is difficulty sleeping, is listed in the official product information as a common psychiatric side effect.

Q: Can Syntaris be taken at the same time as other prescription medications?

A: The concurrent use of Syntaris with all other prescription medications must be reviewed by a healthcare professional. Certain drug classes, such as MAOIs and TCAs, are strictly contraindicated, and patients are advised to disclose all concurrent medications.

Storage and Disposal Conditions for Syntaris (Flunisolide Nasal Solution)

Syntaris must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The nasal solution must be protected from heat and direct light, and it is essential that the product not be frozen.

---

Container and Stability

The container should be kept tightly closed and stored in an upright position. The product must be discarded three months after opening or once the labeled number of metered sprays has been used. Like all medicines, Syntaris must be kept out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Syntaris must be disposed of according to local regulations for pharmaceutical waste. Patients should consult a pharmacist or local authority for safe disposal programs; the product should not be flushed down a toilet or poured into a drain.